Primer | Sequence | Note | |
---|---|---|---|
iNOS | Forward | 5ʹ- CCCTTCCGAAGTTTCTGGCAGCAG − 3ʹ | In vitro study |
Reverse | 5ʹ - GGCTGTCAGAGCCTCGTGGCTTTGG − 3ʹ | ||
Arg-1 | Forward | 5ʹ - TCATCTGGGTGGATGCTCACAC − 3ʹ | |
Reverse | 5ʹ - GAGAATCCTGGCACATCGGGAA − 3ʹ | ||
CCL5 | Forward | 5ʹ- CCTGCTGCTTTGCCTACATTGC − 3ʹ | |
Reverse | 5ʹ- ACACACTTGGCGGTTCTTTCGG − 3ʹ | ||
CCL17 | Forward | 5ʹ- CACGCAGCTCGAGGGACCAATGTG − 3ʹ | |
Reverse | 5ʹ- TCAAGACCTCTCAAGGCTTTGCAGG − 3ʹ | ||
GAPDH | Forward | 5ʹ- AGGTCGGTGTGAACGGATTTG − 3ʹ | |
Reverse | 5ʹ- TGTAGACCATGTAGTTGAGGTCA − 3ʹ | ||
IL-6 | Forward | 5ʹ- CCCTGCAGCTGGAGAGTGTGG − 3ʹ | In vivo study |
Reverse | 5ʹ- TGTGCTCTGCTTGAGAGGTGCT − 3ʹ | ||
IL-1β | Forward | 5ʹ- CCCTGAACTCAACTGTGAAATAGCA − 3ʹ | |
Reverse | 5ʹ- CCCAATCAAGGGCTTGGAA − 3ʹ | ||
IL-10 | Forward | 5ʹ- TCCGGGGTGACAATAACTGC − 3ʹ | |
Reverse | 5ʹ- GCAGCTGTATCCAGAGGGTC − 3ʹ | ||
GAPDH | Forward | 5ʹ- TTCAACGGCACAGTCAAGG − 3ʹ | |
Reverse | 5ʹ- CTCAGCACCAGCATCACC − 3ʹ |